Leading companies in longevity and anti-aging

BioAge Labs uses artificial intelligence and omics data to identify aging biomarkers and develop drugs. Its focus on AI-driven drug discovery for aging pathways makes it a promising company.

Grupo Neolife is a specialist in preventive anti-aging medicine in Spain, offering advanced check-ups and personalized hormone therapy programs. Their focus on preventive medicine and age management positions them as leaders in the field of longevity in Spain.

Altos Labs is a pioneering company in cellular rejuvenation therapies, focusing on epigenetic reprogramming to reverse aging at a molecular level. Its unprecedented funding and expected human clinical trials by 2026 position it as a leader.

Retro Biosciences invests heavily in plasma-based therapies and cellular repair technologies, with the goal of extending healthy lifespan by 10 years. In 2026, they are expected to announce clinical trial results that could be revolutionary.

Co-founded by David Sinclair, this company focuses on cellular rejuvenation therapies through partial epigenetic reprogramming. In January 2026, the FDA authorized human clinical trials for its gene therapy ER-100, a significant milestone.

Cambrian Biopharma operates as a 'company builder,' funding multiple therapeutic programs simultaneously, from senescent cell clearance to immunological rejuvenation. Its distributed R&D model makes it a central player in longevity biotechnology.

Gero is an AI-driven drug discovery company focused on age-related diseases. In July 2025, it announced a research and licensing agreement with Chugai Pharmaceutical, validating its AI platform.

Turn Biotechnologies develops epigenetic reprogramming technologies and mRNA-based therapies for age-related diseases. In March 2025, it acquired technology to enhance the delivery of its therapies, demonstrating continuous progress.

Rubedo Life Sciences develops therapies that selectively eliminate senescent cells, the 'zombie cells' that contribute to aging. In May 2025, it received FDA authorization for its drug RLS-1496, with a Phase 1b/2a study planned.

Calico Labs, an Alphabet (Google) project, focuses on understanding the molecular mechanisms of aging and developing technologies to extend lifespan. Its partnership with AbbVie for neurodegenerative treatments keeps it relevant in 2026.

Oisín Biotechnologies develops anti-aging treatments that eliminate senescent cells, which contribute to age-related diseases. By 2026, its drug delivery platform has entered Phase 1 trials for cardiovascular aging, highlighting it in the field.

Unity Biotechnology specializes in senescence-targeted therapies, developing drugs to eliminate senescent cells that drive aging. It continues to be a key player in the development of senolytics, aiming to delay or reverse aging diseases.

Insilico Medicine combines artificial intelligence with biology to discover new longevity treatments. In 2026, its first AI-discovered drug is in Phase 2 trials, attracting attention as a promising longevity action.

Human Longevity Inc. is a genomics-based health intelligence company that empowers proactive healthcare. It focuses on shifting medicine from reactive to proactive for diseases like cancer and diabetes, making it relevant in today's longevity landscape.

BioViva USA Inc. is a leader in gene therapy innovation, seeking to treat severe genetic disorders and cellular aging. Its focus on gene therapy for cellular aging keeps it at the forefront of longevity solutions in 2026.

Cenegenics is a pioneer in longevity medicine with over 25 years of experience in age management. They offer advanced medical therapies and preventive check-ups based on biomarkers, providing a guided 360° clinical approach to longevity.